Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic breast cancer in postmenopausal women with oestrogen-receptor positive tumours Age: Adult |
Dose: Intramuscular – 500 mg (250 mg into each buttock) Frequency: on days 1, 15, and 29, then once monthly thereafter |
|
Indication: Metastatic breast cancer in postmenopausal women with oestrogen-receptor positive tumours Age: Adult Condition: Moderate (Child-Pugh Class B) |
Dose: Intramuscular – 250 mg (into 1 buttock) Frequency: on days 1, 15, and 29, then once monthly thereafter |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Injection – Negligible amounts Note: Negligible amounts of fulvestrant are eliminated in urine. In clinical trials, fulvestrant concentrations in women with estimated creatinine clearance greater than or equal to 30 mL/minute were similar to women with normal creatinine. |
Administration
- Given as intramuscular injection
- Must be administered by healthcare professionals
Side Effect
- Nausea (26%)
- Asthenia (23%)
- Pain (19%)
- Vasodilatation (18%)
- Pharyngitis (16%)
- HA (15%)
- Back pain (14%)
- Constipation (13%)
- Vomiting (13%)
- Abd pain (12%)
- Diarrhea (12%)
- Injection site pain (11%)
- Cough (10%)
- Anorexia (9%)
- Peripheral edema (9%)
- Chest pain (7%)
- Flu-like syndrome (7%)
- Rash (7%)
- Depression (6%)
- Fever (6%)
- UTI (6%)
- Anemia (5%)
- Angioedema
- Leukopenia
- Myalgia
- Thrombosis
- Osteoporosis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban)
|
Increased risk of bleeding when taken concomitantly
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.